April 17, 2018 / 7:07 PM / 4 days ago

BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN

April 17 (Reuters) - INNATE PHARMA SA:

* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN

* 8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL

* NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED

* COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS

* TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED Source text: bit.ly/2J3tCYk Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below